The emergence of T-cell therapy has fundamentally reshaped the approach to preventing and treating viral infections in patients undergoing allogeneic haemopoietic stem cell transplantation (HSCT).
Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients. While the procedure offers hope for many, infections remain ...
Findings from cohort 2 showed SER-155 reduced the relative risk of bacterial BSIs by 77% compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma Allogeneic hematopoietic stem cell ...
Seres seeking SER-155 strategic partnership to accelerate next study in allo-HSCT and expand to multiple target populations CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc.
Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial ...
AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of increased ...
Consolidation and maintenance therapy with Ninlaro post-HSCT significantly improves progression-free survival compared to observation in relapsed multiple myeloma patients. The Myeloma XII (ACCorD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results